RAPT Therapeutics, Inc. (RAPT)
Automate Your Wheel Strategy on RAPT
With Tiblio's Option Bot, you can configure your own wheel strategy including RAPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RAPT
- Rev/Share 0.0
- Book/Share 5.6365
- PB 10.2333
- Debt/Equity 0.0171
- CurrentRatio 12.0407
- ROIC -0.7287
- MktCap 953882423.0
- FreeCF/Share -3.2142
- PFCF -11.0067
- PE -14.7224
- Debt/Assets 0.0157
- DivYield 0
- ROE -0.6181
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RAPT | Piper Sandler | -- | Overweight | -- | $95 | Jan. 9, 2026 |
| Initiation | RAPT | Guggenheim | -- | Buy | -- | $70 | Oct. 27, 2025 |
| Upgrade | RAPT | JP Morgan | Neutral | Overweight | -- | $55 | Oct. 20, 2025 |
| Initiation | RAPT | Barclays | -- | Overweight | -- | $35 | Oct. 13, 2025 |
| Upgrade | RAPT | Leerink Partners | Market Perform | Outperform | -- | $37 | Sept. 26, 2025 |
| Upgrade | RAPT | JP Morgan | Underweight | Neutral | -- | $14 | July 30, 2025 |
| Resumed | RAPT | H.C. Wainwright | -- | Buy | -- | $6 | May 22, 2025 |
| Upgrade | RAPT | H.C. Wainwright | Neutral | Buy | -- | $10 | Dec. 26, 2024 |
News
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
Read More
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
Read More
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
Published: January 20, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc.
Read More
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
Published: January 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ: RAPT) in a transaction valued at $2.2 billion.
Read More
Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Published: January 20, 2026 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE, Jan. 20, 2026 /PRNewswire/ -- Ademi LLP is investigating RAPT (NASDAQ: RAPT) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with GSK plc. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in September:
Read More
Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 101.02%: Read This Before Placing a Bet
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 101% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Rapt Therapeutics (RAPT) could be a good stock pick from a technical perspective. RAPT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 122.2% in Rapt Therapeutics (RAPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Best Momentum Stocks to Buy for July 15th
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025.
Read More
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to …
Read More
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About RAPT Therapeutics, Inc. (RAPT)
- IPO Date 2019-10-31
- Website https://www.rapt.com
- Industry Biotechnology
- CEO Brian Russell Wong
- Employees 67